Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vlad Popovici

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Molecular Cancer Therapeutics|February 28, 2018
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic <i>BRAF</i> Mutant Colorectal CancerNicholas Forsythe, Alaa Refaat, Arman Javadi, et al.
Breast Cancer Research : BCR|January 13, 2010
Effect of training-sample size and classification difficulty on the accuracy of genomic predictorsVlad Popovici, Weijie Chen, Brandon G Gallas, et al.
Plos One|August 4, 2012
A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterationsTao Xie, Giovanni D' Ario, John R Lamb, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
BMC Cancer|April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)Francesca Aroldi, Elena Elez, Thierry André, et al.
Nature Medicine|June 3, 2025
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancerGianmarco Piccinno, Kelsey N Thompson, Paolo Manghi, et al.
Nature Biotechnology|August 3, 2010
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsLeming Shi, Gregory Campbell, Wendell D Jones, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Molecular Cancer Therapeutics|February 28, 2018
The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic <i>BRAF</i> Mutant Colorectal CancerNicholas Forsythe, Alaa Refaat, Arman Javadi, et al.
Breast Cancer Research : BCR|January 13, 2010
Effect of training-sample size and classification difficulty on the accuracy of genomic predictorsVlad Popovici, Weijie Chen, Brandon G Gallas, et al.
Plos One|August 4, 2012
A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterationsTao Xie, Giovanni D' Ario, John R Lamb, et al.
BJC Reports|March 27, 2025
A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancersPeter Gallagher, Christian Rolfo, Elena Elez, et al.
BMC Cancer|April 11, 2025
A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)Francesca Aroldi, Elena Elez, Thierry André, et al.
Nature Medicine|June 3, 2025
Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancerGianmarco Piccinno, Kelsey N Thompson, Paolo Manghi, et al.
Nature Biotechnology|August 3, 2010
The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive modelsLeming Shi, Gregory Campbell, Wendell D Jones, et al.
Pageof 4